文献速递血栓与止血

艾美赛珠单抗的数学分析:亲和力驱动的复合物形成与脂质表面反应

Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions.
PubMed 文献 · J Thromb Haemost · 2025-07-16

本研究通过扩展组织因子(TF):VIIa激活FX的数学模型并纳入艾美赛珠单抗与FIXa的相互作用,结合实验数据校准,发现高浓度艾美赛珠单抗通过减少FX与脂质表面及TF:VIIa的结合来抑制TF:VIIa对FX的激活,而脂质增强艾美赛珠单抗存在下FX对FIXa的激活。

要点

  • 高浓度艾美赛珠单抗抑制TF:VIIa激活FX,模型需假设艾美赛珠单抗结合的FX部分受限才能解释。
  • 脂质增强艾美赛珠单抗存在下FX对FIXa的激活,模型成功预测多种实验条件下FIXa激活FX。
  • 敏感性分析显示结合臂亲和力影响反应速度,艾美赛珠单抗优先结合脂质结合的FX和FIXa。

核心结论

  • 高浓度艾美赛珠单抗通过减少FX与脂质表面和TF:VIIa的结合来降低TF:VIIa对FX的激活。
  • 艾美赛珠单抗通过优先结合脂质结合的FX并随后结合脂质结合的FIXa,且因脂质表面共定位而增强结合速率,从而增强脂质表面上FIXa对FX的激活。

研究设计与样本

  • 研究通过数学建模与生化实验相结合,扩展了TF:VIIa激活FX的数学模型以纳入艾美赛珠单抗与FIXa的相互作用,并使用实验数据校准模型。

主要发现

  • 高浓度艾美赛珠单抗抑制TF:VIIa对FX的激活。
  • 数学模型仅在假设艾美赛珠单抗结合的FX部分受限无法结合脂质表面和TF:VIIa时才能解释上述观察。
  • 脂质增强艾美赛珠单抗存在下FX对FIXa的激活。
  • 在双臂相互作用模型中估计了脂质表面上艾美赛珠单抗依赖性FX激活的动力学速率。
  • 模型成功预测了有无艾美赛珠单抗时FIXa对FX的激活,涵盖多种实验条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emicizumab is a bispecific antibody that binds activated factor (F)IXa with 1-arm and FX with the other. Binding bridges FIXa and FX, replacing the function of FVIII in hemophilia A. Unlike FVIII, emicizumab does not bind directly to lipid surfaces. OBJECTIVES: This study aimed to investigate emicizumab's lipid-surface dependent mechanisms through mathematical modeling and biochemical assays. METHODS: We expanded our mathematical model of tissue factor (TF):VIIa activation of FX to incorporate emicizumab and FIXa interactions. We calibrated our model using experimental data. RESULTS: High concentrations of emicizumab inhibit FX activation by TF:VIIa. Our mathematical model explains these observations only when FX bound to emicizumab is partially restricted from binding to lipid surfaces and to TF:VIIa. Lipid enhances FX activation of FIXa in the presence of emicizumab. In our 2-arm interaction model, we estimated kinetic rates for emicizumab-dependent activation of FX on the lipid surface. The model successfully predicted FIXa activation of FX with and without emicizumab across many experimental conditions. Ternary complexes (FIXa, FX, and emicizumab) in solution decreased when lipid increased while ternary complexes on lipid increased. Sensitivity analysis, which varied lipid, dissociation constants, and catalytic rates, highlighted the impact of binding-arm affinity on reaction velocities. CONCLUSION: High concentrations of emicizumab decrease TF:VIIa activation of FX by reducing FX binding to both the lipid surface and TF:VIIa. Emicizumab enhances FIXa activation of FX on the lipid surface by preferentially binding to lipid-bound FX and subsequently to lipid-bound FIXa with an enhanced association rate due to colocalization on the lipid surface.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Madrigal J, Monroe DM, Sindi SS, et al. Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions. J Thromb Haemost. 2025. PMID: 40680939. doi:10.1016/j.jtha.2025.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。